Nanobiotix S.A. - Sponsored ADR (NASDAQ:NBTX) Sees Large Growth in Short Interest

Key Points

• Nanobiotix S.A. experienced a significant increase in short interest in September, rising by 572.7% to a total of 74,000 shares.
• The company has received mixed ratings from analysts, with Weiss Ratings giving a sell rating, while HC Wainwright maintains a buy rating.
• As of the latest trading, Nanobiotix shares reached $26.15, with a 52-week range between $2.76 and $30.35.

Nanobiotix S.A. - Sponsored ADR (NASDAQ:NBTX - Get Free Report) was the target of a large increase in short interest in the month of September. As of September 30th, there was short interest totaling 74,000 shares, an increase of 572.7% from the September 15th total of 11,000 shares. Based on an average trading volume of 51,600 shares, the short-interest ratio is currently 1.4 days. Based on an average trading volume of 51,600 shares, the short-interest ratio is currently 1.4 days.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on NBTX shares. Weiss Ratings reissued a "sell (d-)" rating on shares of Nanobiotix in a research report on Wednesday, October 8th. Leerink Partners set a $14.00 price target on shares of Nanobiotix in a report on Thursday, September 18th. Finally, HC Wainwright restated a "buy" rating on shares of Nanobiotix in a research report on Friday, September 19th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Hold" and a consensus target price of $11.00.

Nanobiotix Stock Performance

Shares of NASDAQ:NBTX traded down $0.42 during trading on Friday, reaching $26.15. 28,586 shares of the company traded hands, compared to its average volume of 27,703. Nanobiotix has a 52 week low of $2.76 and a 52 week high of $30.35. The company's 50 day moving average is $13.79 and its two-hundred day moving average is $7.66.

About Nanobiotix

Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.